The code appears to be a misnomer or a very specific internal project identifier for which there is no broad public record. However, it is most frequently associated in recent medical research contexts with TRG-035 , a groundbreaking tooth regeneration drug currently undergoing human clinical trials in Japan.
Below is an overview of the development and science behind . TRG-035: The World's First Tooth Regrowth Drug
If clinical trials continue to show success, researchers aim to make TRG-035 commercially available by . This would offer a biological alternative to traditional prosthetic solutions like dental implants, bridges, or dentures. Japan Begins Human Trials for Tooth Regrowth Drug TRG-035 NEWM-035
: Success in Phase I will lead to trials for children aged 2–7 with congenital anodontia (being born without a full set of teeth). Future Outlook
The drug was developed by , a spinoff from Kyoto University, led by Dr. Katsu Takahashi. The code appears to be a misnomer or
: Preclinical trials on mice and ferrets—chosen for their similar dental structures—successfully produced new teeth with normal enamel and root structures and no significant side effects.
TRG-035 is a monoclonal antibody designed to stimulate the growth of a "third set" of teeth in humans who have lost them due to decay, injury, or congenital conditions. TRG-035: The World's First Tooth Regrowth Drug If
: Launched in September 2024 at Kyoto University Hospital. This phase involves 30 healthy adult males aged 30–64 who are missing at least one molar, primarily focusing on safety and dosage.